Cost-effectiveness analysis of baseline testing for resistance-associated polymorphisms to optimize treatment outcome in genotype 1 noncirrhotic treatment-naïve patients with chronic hepatitis C virus

<p><strong>Objectives:</strong> Direct-acting antivirals containing nonstructural protein 5A (NS5A) inhibitors administered over 8 to 12 weeks are effective in &sim;95% of patients with hepatitis C virus. Nevertheless, patients resistant to NS5A inhibitors have lower c...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй
Үндсэн зохиолчид:	Fawsitt, C, Vickerman, P, Cooke, G, Barnes, E, Ball, J, Brainard, D, Burgess, G, Dillon, J, Foster, G, Gore, C, Guha, N, Halford, R, Whitby, K, Holmes, C, Howe, A, Hudson, E, Hutchinson, S, Irving, W, Khakoo, S, Klenerman, P, Martin, N, Massetto, B, Mbisa, T, McHutchison, J, McKeating, J, McLauchlan, J, Miners, A, Murray, A, Shaw, P, Simmonds, P, Spencer, C, Thomson, E, Zitzmann, N, Welton, N
Формат:	Journal article
Хэл сонгох:	English
Хэвлэсэн:	Elsevier 2019

Cost-effectiveness analysis of baseline testing for resistance-associated polymorphisms to optimize treatment outcome in genotype 1 noncirrhotic treatment-naïve patients with chronic hepatitis C virus

Ижил төстэй зүйлс